Biotherapeutic manufacturers must move beyond traditional batch and fed-batch processing and look to adopt continuous approaches to increase dose production, reduce costs, and maintain consistent quality. Join a panel of experts from Repligen as we discuss how the lessons learned from monoclonal antibodies (mAbs) production can be applied to advanced therapeutic medicinal products (ATMPs) including gene therapies, cell therapies, nucleic acid-based therapies, oncolytics, vaccines, and exosomes.
Webinar Learning Objectives
Understand the innovative technologies and strategies that led to boosted mAbs productivity, reduced COGS, and improved quality.
Examine how scalable N perfusion and intensified fed-batch using N-1 perfusion in mAbs and viral vector production can lead to 3X improvements in space-time yield.
Learn how to overcome the unique challenges of advanced therapeutics, ensuring higher productivity, scalability, and cost-effectiveness in ATMP manufacturing.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
